From FDA and Health Canada approvals to joint ventures, here are 7 medtech stories we missed this week but thought were still worth mentioning. 1. FDA clears Joimax Endovapor 2 Joimax announced in an April 26 press release that it has received FDA 510(k) clearance to market its Endovapor 2 Multi-Radio Frequency System. The device […]
FDA warns Eclipse Aesthetics on MicroPen personal dermabrasion device
The FDA recently released a warning letter it sent to Eclipse Aesthetics, claiming the company lacks appropriate regulatory clearance for its Eclipse Micropen Elite, which it describes as a “dermal micro-needling device” used for skincare applications. The letter came after an FDA inspection in August last year uncovered that the Eclipse MicroPen Elite did not […]
EnteroMedics names ex-Lanx chief Gladney as CEO | Personnel Moves
EnteroMedics (NSDQ:ETRM) said it named Dan Gladney, the former chief executive who led Lanx to an acquisition by Biomet, to be its new CEO effective Nov. 16. St. Paul, Minn.-based EnteroMedics said chairman, president & CEO Mark Knudson will become executive chairman when Gladney takes over the corner office until Jan. 1, 2016, when he will […]
Syneron settles patent lawsuit against EndyMed
Syneron Medical (NSDQ:ELOS) dropped a patent infringement lawsuit against EndyMed Medical and its distributor, Eclipse Aesthetics, after EndyMed agreed to stop selling its fractional skin resurfacing products in the U.S.
EndyMed will continue to re-supply electrodes and other maintenance items for the products it has already sold, according to a press release.
Syneron sues aesthetics duo over skin-tightening technology
Israel-based maker Syneron Medical (NSDQ:ELOS) sued a pair of rival companies over devices that allegedly infringe on 2 Syneron patents for skin ablation technology.
Syneron claimed that EndyMed Medical and Eclipse Aesthetics infringe on the patents by selling use electrodes to apply ablative energy to the skin.
